Advertisements


Citi finds biotech executives jump ship ahead of bad drug trials

Analysis confirms what many on the Street were already thinking: biotech executives leaving ahead of late-stage clinical data often means the study will fail, according to one Citi’s Yigal... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkJul 2nd, 2019

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. read more.....»»

Category: blogSource: benzingaJun 29th, 2019

FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule

Micro-cap biotech Ocular Therapeutix Inc (NASDAQ: OCUL) announced Friday that it received FDA approval for an expanded indication for its eye pain drug. read more.....»»

Category: blogSource: benzingaJun 21st, 2019

The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. read more.....»»

Category: blogSource: benzingaJun 1st, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis drug Skyrizi received FDA nod. The week also saw the release of strong quarterly earnings by big European pharma gian.....»»

Category: earningsSource: benzingaApr 27th, 2019

How free-flowing cash is accelerating small companies" cancer drug trials

An unprecedented biotech investment boom means smaller companies can accelerate early-stage drug trials and, potentially, carry them to more patients faster......»»

Category: topSource: bizjournalsApr 8th, 2019

5 biotech stocks that could be the next big winners

Pick your spots based on either high-potential drug trials or the likelihood of an acquisition......»»

Category: topSource: moneycentralMar 25th, 2019

Jeff Reeves"s Strength in Numbers: 5 biotech stocks that could be the next big winners

Pick your spots based on either high-potential drug trials or the likelihood of an acquisition......»»

Category: topSource: marketwatchMar 25th, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Biotech stocks came under pressure last week despite two FDA approvals coming through. read more.....»»

Category: blogSource: benzingaMar 23rd, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ:.....»»

Category: earningsSource: benzingaMar 23rd, 2019

Brainstorm Health: Biogen Alzheimer’s Drug, CVS Meets CBD, New CRISPR Company

Brainstorm Health Daily: March 21, 2019 Good afternoon, readers. It was a sad day for biopharma. Yet again, an Alzheimer’s drug hopeful crashed and burned in critical late-stage clinical trials. The victim, this time, was biotech gian.....»»

Category: europeSource: fortuneMar 21st, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

It was an event-filled one for biotech stocks, with the release of a slew of earnings, presentations of clinical trial results an.....»»

Category: earningsSource: benzingaMar 3rd, 2019

After headline drug flops in trials, Peninsula biotech sheds 70% of its value

The South San Francisco company halted development of a drug for a rare protein-misfolding condition that causes heart problems, resulting in a $534 million drop in market value......»»

Category: topSource: bizjournalsApr 23rd, 2018

The Tell: Executives expect U.S. deal-making pace to pick up steam in year ahead: survey

Top executives expect the pace of U.S. deal making to accelerate in the year ahead, fueled in part by the desire to acquire talent and keep up with technological innovation, a survey finds......»»

Category: topSource: marketwatchApr 16th, 2018

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

After a lackluster show mid-way through the week despite M&A news and earnings, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) staged a recovery in the later part of the week. As the sector struggle.....»»

Category: earningsSource: benzingaApr 29th, 2018

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

After a lackluster show mid-way through the week despite M&A news and earnings, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) staged a recovery in the later part of the week. read more.....»»

Category: blogSource: benzingaApr 29th, 2018

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Wedbush analysts see an attractive entry point for Alpine Immune Sciences Inc. (NASDAQ: ALPN), as the biotech's initial candidates will enter the clinic over the next year. Latest Ratings fo.....»»

Category: blogSource: benzingaMay 18th, 2018

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. read more.....»»

Category: blogSource: benzingaJun 10th, 2018

Former Puma Biotech executive gets U.S. prison term for insider trading

BOSTON (Reuters) - A former Puma Biotechnology Inc executive was sentenced on Wednesday to 2-1/4 years in prison for trading on inside information ahead of announcements by the biopharmaceutical company about a breast cancer drug it was developing......»»

Category: topSource: reutersJun 20th, 2018

Guggenheim exec, brother of CEO, departs troubled firm

Troubled asset manager Guggenheim Partners has seen a number of executives jump ship. The latest is Patrick Walter, Guggenheim Partners’s head of human resources. Walter is leaving the New York investment advisory firm after a series of disput.....»»

Category: topSource: bizjournalsJun 29th, 2018

More upside ahead for Biogen, says Jerry Braakman

First American Trust's CIO tells Reuters' Fred Katayama why he's bullish on Biogen's prospects. The biotech firm's stock surged after its Alzheimer's drug showed positive results in a mid-stage trial......»»

Category: videoSource: reutersJul 6th, 2018